Long-Lasting Tissue Inflammatory Processes Trigger Autoimmune Responses to Extracellular Matrix Molecules

REFERENCES

• Bosman F., Stamenkovic I. Functional structure and composition of extracellular matrix. J. Pathol. 2003; 200: 423–428
   PubMed Web of Science ®Google Scholar
• Nelson C. M., Bissell M. J. Of extracellular matrix, scaffolds, and signalling: tissue architecture regulates development, homeostasis, and cancer. Annu. Rev. Cell. Dev. Biol. 2006; 22: 287–309
   PubMed Web of Science ®Google Scholar
• Adachi E., Hopkinson I., Hayashi T. Basement-membrane stromal relationships: interactions between collagen fibrils and the lamina densa. Int. Rev. Cytol. 199; 173: 73–156
   Google Scholar
• Paulsson M. Basement membrane proteins: structure, assembly, and cellular interactions. Crit. Rev. Biochem. Mol. Biol. 1992; 27: 93–127
   PubMed Web of Science ®Google Scholar
• Gelse K., Poschl E., Aigner T. Collagens–structure, function, and biosynthesis. Adv. Drug. Deliv. Rev. 2003; 55: 1531–1546
   PubMed Web of Science ®Google Scholar
• Kuivaniemi H., Tromp G., Prockop D. J. Mutations in collagen genes: causes of rare and some common diseases in humans. FASEB J. 1991; 5: 2052–2060
   PubMed Web of Science ®Google Scholar
• Traub W., Piez K. A. The chemistry and structure of collagen. Adv. Protein Chem. 1971; 25: 243–352
   PubMedGoogle Scholar
• Ricard-Blum S., Ruggiero F. The collagen superfamily: from the extracellular matrix to the cell membrane. Pathol. Biol. (Paris) 2005; 53: 430–442
   PubMed Web of Science ®Google Scholar
• Antonicelli F., Bellon G., Debelle L., Hornebeck W. Elastin-elastases and inflamm-aging. Curr. Top. Dev. Biol. 2007; 79: 99–155
   PubMed Web of Science ®Google Scholar
• Culav E. M., Clark C. H., Merrilees M. J. Connective tissues: matrix composition and its relevance to physical therapy. Phys. Ther. 1999; 79: 308–319
   PubMed Web of Science ®Google Scholar
• Cattaruzza S., Perris R. Approaching the proteoglycome: molecular interactions of proteoglycans and their functional output. Macromol. Biosci. 2006; 6: 667–680
   PubMed Web of Science ®Google Scholar
• Hohenester E., Engel J. Domain structure and organisation of extracellular matrix proteins. Matrix Biol. 2002; 21: 115–128
   PubMed Web of Science ®Google Scholar
• Raghow R. The role of extracellular matrix in postinflammatory wound healing and fibrosis. FASEB J. 1994; 8: 823–831
   PubMed Web of Science ®Google Scholar
• Hsia H. C., Schwarzbauer J. E. Meet the tenascins: multifunctional and mysterious. J. Biol. Chem. 2005; 280: 26641–26644
   PubMed Web of Science ®Google Scholar
• Nathan C. Points of control in inflammation. Nature 2002; 420: 846–852
   PubMed Web of Science ®Google Scholar
• McIntyre T. M., Prescott S. M., Weyrich A. S., Zimmerman G. A. Cell-cell interactions: leukocyte-endothelial interactions. Curr. Opin. Hematol. 2003; 10: 150–158
   PubMed Web of Science ®Google Scholar
• Manzo A., Caporali R., Montecucco C., Pitzalis C. Role of chemokines and chemokine receptors in regulating specific leukocyte trafficking in the immune/inflammatory response. Clin. Exp. Rheumatol. 2003; 21: 501–508
   PubMedGoogle Scholar
• Louis N. A., Hamilton K. E., Colgan S. P. Lipid mediator networks and leukocyte transmigration. Prostaglandins Leukot. Essent. Fatty Acids 2005; 73: 197–202
   PubMedGoogle Scholar
• Monaco C., Andreakos E., Kiriakidis S., Feldmann M., Paleolog E. T-cell-mediated signalling in immune, inflammatory and angiogenic processes: the cascade of events leading to inflammatory diseases. Curr. Drug Targets Inflamm. Allergy 2004; 3: 35–42
   PubMedGoogle Scholar
• Martins P. S., Kallas E. G., Neto M. C., Dalboni M. A., Blecher S. and R. Salomão, Upregulation of reactive oxygen species generation and phagocytosis, and increased apoptosis in human neutrophils during severe sepsis and septic shock. Shock 2003; 20: 208–212
   PubMed Web of Science ®Google Scholar
• Carletto A., Bellavite P., Guarini P., Biasi D., Chirumbolo S., Caramaschi P., Bambara L. M., Corrocher R. Changes of fatty acid composition and oxidative metabolism of human neutrophils migrating into an inflammatory exudate. Inflammation 1996; 20: 123–137
   PubMedGoogle Scholar
• Mantovani A. The interplay between primary and secondary cytokines. Cytokines involved in the regulation of monocyte recruitment. Drugs 1997; 54(Suppl 1)15–23
   PubMedGoogle Scholar
• Furie M. B., Randolph G. J. Chemokines and tissue injury. Am. J. Pathol. 1995; 146: 1287–1301
   PubMed Web of Science ®Google Scholar
• Mantovani A., Garlanda C., Locati M., Rodriguez T. V., Feo S. G., Savino B., Vecchi A. Regulatory pathways in inflammation. Autoimmun. Rev. 2007; 7: 8–11
   PubMedGoogle Scholar
• Mantovani A., Bonecchi R., Martinez F. O., Galliera E., Perrier P., Allavena P., Locati M. Tuning of innate immunity and polarized responses by decoy receptors. Int. Arch. Allergy Immunol. 2003; 132: 109–15
   PubMed Web of Science ®Google Scholar
• Buckley C. D., Pilling D., Lord J. M., Akbar A. N., Scheel-Toellner D., Salmon M. Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation. Trends Immunol. 2001; 22: 199–204
   PubMed Web of Science ®Google Scholar
• Lawrence T., Gilroy D. W. Chronic inflammation: a failure of resolution?. Int. J. Exp. Pathol. 2007; 88: 85–94
   PubMed Web of Science ®Google Scholar
• Opdenakker G., Dillen C., Fiten P., Martens E., Van Aelst I., Van den Steen P. E., Nelissen I., Starckx S., Descamps F. J., Hu J., Piccard H., Van Damme J., Wormald M. R., Rudd P. M., Dwek R. A. Remnant epitopes, autoimmunity and glycosylation. Biochim. Biophys. Acta. 2006; 1760: 610–615
   PubMed Web of Science ®Google Scholar
• Descamps F. J., Van den Steen P. E., Nelissen I., Van Damme J., Opdenakker G. Remnant epitopes generate autoimmunity: from rheumatoid arthritis and multiple sclerosis to diabetes. Adv. Exp. Med. Biol. 2003; 535: 69–77
   PubMedGoogle Scholar
• Van den Steen P. E., Proost P., Grillet B., Brand D. D., Kang Damme A. H., Van J., Opdenakker G. Cleavage of denatured natural collagen type II by neutrophil gelatinase B reveals enzyme specificity, post-translational modifications in the substrate, and the formation of remnant epitopes in rheumatoid arthritis. FASEB J. 2002; 16: 379–389
   PubMedGoogle Scholar
• Van den Steen P. E., Grillet B., Opdenakker G. Gelatinase B participates in collagen II degradation and releases glycosylated remnant epitopes in rheumatoid arthritis. Adv. Exp. Med. Biol. 2005; 564: 45–55
   PubMed Web of Science ®Google Scholar
• Moudgil K. D., Sercarz E. E. Understanding crypticity is the key to revealing the pathogenesis of autoimmunity. Trends Immunol. 2005; 26: 355–359
   PubMed Web of Science ®Google Scholar
• Hogquist K. A., Baldwin T. A., Jameson S. C. Central tolerance: learning self-control in the thymus. Nat. Rev. Immunol 2005; 5: 772–782
   PubMed Web of Science ®Google Scholar
• van den Boorn J. G., Le Poole I. C., Luiten R. M. T-cell avidity and tuning: the flexible connection between tolerance and autoimmunity. Int. Rev. Immunol. 2006; 25: 235–258
   PubMed Web of Science ®Google Scholar
• Setiady Y. Y., Agersborg S., Samy E. T., Lewis J. E., Tung K. S. Neonatal autoimmune disease: influence of CD4+ CD25+ regulatory T cells. Int. Rev. Immunol. 2005; 24: 227–45
   PubMed Web of Science ®Google Scholar
• Guerder S., Flavell R. A. Costimulation in tolerance and autoimmunity. Int. Rev. Immunol. 1995; 13: 135–146
   PubMedGoogle Scholar
• Wardemann H., Nussenzweig M. C. B-cell self-tolerance in humans. Adv. Immunol. 2007; 95: 83–110
   PubMed Web of Science ®Google Scholar
• Lohr J., Knoechel B., Nagabhushanam V., Abbas A. K. T-cell tolerance and autoimmunity to systemic and tissue-restricted self-antigens. Immunol. Rev. 2005; 204: 116–27
   PubMed Web of Science ®Google Scholar
• Vanderlugt C. L., Miller S. D. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat. Rev. Immunol. 2002; 2: 85–95
   PubMed Web of Science ®Google Scholar
• Lehmann P. V., Forsthuber T., Miller A., Sercarz E. E. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 1992; 358: 155–157
   PubMed Web of Science ®Google Scholar
• Sercarz E. E., Lehmann P. V., Ametani A., Benichou G., Miller A., Moudgil K. Dominance and crypticity of T cell antigenic determinants. Annu. Rev. Immunol. 1993; 11: 729–766
   PubMed Web of Science ®Google Scholar
• Goetzl E. J., Banda M. J., Leppert D. Matrix metalloproteinases in immunity. J. Immunol. 1996; 156: 1–4
   PubMed Web of Science ®Google Scholar
• Ratner S. Lymphocyte migration through extracellular matrix. Invasion Metastasis 1992; 12: 82–100
   PubMedGoogle Scholar
• Schor H., Vaday G. G., Lider O. Modulation of leukocyte behavior by an inflamed extracellular matrix. Dev. Immunol. 2000; 7: 227–238
   PubMedGoogle Scholar
• Woessner J. F., Jr. The family of matrix metalloproteinases. Ann. N. Y. Acad. Sci. 1994; 732: 11–21
   PubMed Web of Science ®Google Scholar
• Lemaitre V., D'Armiento J. Matrix metalloproteinases in development and disease. Birth Defects Res. (Part C) 2006; 78: 1–10
   PubMedGoogle Scholar
• Brinckerhoff C. E., Matrisian L. M. Matrix metalloproteinases: a tail of a frog that became a prince. Nat. Rev. Mol. Cell. Biol. 2002; 3: 207–214
   PubMed Web of Science ®Google Scholar
• Andreasen P. A., Egelund R., Petersen H. H. The plasminogen activation system in tumor growth, invasion, and metastasis. CMLS, Cell. Mol. Life Sci. 2000; 57: 25–40
   PubMed Web of Science ®Google Scholar
• Fu X., Parks W. C., Heinecke J. W. Activation and silencing of matrix metalloproteinases. Semin. Cell Dev. Biol. 2008; 19: 2–13
   PubMed Web of Science ®Google Scholar
• Massova I., Kotra L. P., Fridman R., Mobashery S. Matrix metalloproteinases: structures, evolution, and diversification. FASEB J. 1998; 12: 1075–1095
   PubMed Web of Science ®Google Scholar
• Tang B. L. ADAMTS: a novel family of extracellular matrix proteases. Int. J. Biochem. Cell. Biol. 2001; 33: 33–44
   PubMed Web of Science ®Google Scholar
• Buhling F., Waldburg N., Reisenauer A., Heimburg A., Golpon H., Welte T. Lysosomal cysteine proteases in the lung: role in protein processing and immunoregulation. Eur. Respir. J. 2004; 23: 620–628
   PubMed Web of Science ®Google Scholar
• Dickinson D. P. Cysteine peptidases of mammals: their biological roles and potential effects in the oral cavity and other tissues in health and disease. Crit. Rev. Oral. Biol. Med. 2002; 13: 238–275
   PubMedGoogle Scholar
• Iredale J. P. A cut above the rest? MMP-8 and liver fibrosis gene therapy. Gastroenterology 2004; 126: 1199–1201
   PubMed Web of Science ®Google Scholar
• Burrage P. S., Mix K. S., Brinckerhoff C. E. Matrix metalloproteinases: role in arthritis. Front. Biosci. 2006; 11: 529–543
   PubMed Web of Science ®Google Scholar
• Shapiro S. D., Senior R. M. Matrix metalloproteinases. Matrix degradation and more. Am. J. Respir. Cell. Mol. Biol. 1999; 20: 1100–1102
   PubMed Web of Science ®Google Scholar
• Chapman H. A., Riese R. J., Shi G. P. Emerging roles for cysteine proteases in human biology. Annu. Rev, Physiol. 1997; 59: 63–88
   PubMed Web of Science ®Google Scholar
• Troen B. R. The regulation of cathepsin K gene expression. Ann. N. Y. Acad. Sci. 2006; 1068: 165–172
   PubMedGoogle Scholar
• Cannon G. J., Swanson J. A. The macrophage capacity for phagocytosis. J. Cell. Sci. 1992; 101: 907–913
   PubMed Web of Science ®Google Scholar
• Wolters P. J., Chapman H. A. Importance of lysosomal cysteine proteases in lung disease. Respir. Res. 2000; 1: 170–177
   PubMedGoogle Scholar
• Lah T. T., Buck M. R., Honn K. V., Crissman J. D., Rao N. C., Liotta L. A., Sloane B. F. Degradation of laminin by human tumor cathepsin B. Clin. Exp. Metastasis 1989; 7: 461–468
   PubMedGoogle Scholar
• Mai J., Sameni M., Mikkelsen T., Sloane B. F. Degradation of extracellular matrix protein tenascin-C by cathepsin B: an interaction involved in the progression of gliomas. Biol. Chem. 2002; 383: 1407–1413
   PubMed Web of Science ®Google Scholar
• Buck M. R., Karustis D. G., Day N. A., Honn K. V., Sloane B. F. Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues. Biochem. J. 1992; 282: 273–278
   PubMedGoogle Scholar
• Pagano M. B., Bartoli M. A., Ennis T. L., Mao D., Simmons P. M., Thompson R. W., Pham C. T. Critical role of dipeptidyl peptidase I in neutrophil recruitment during the development of experimental abdominal aortic aneurysms. Proc. Natl. Acad. Sci. U. S.A 2007; 104: 2855–2860
   PubMed Web of Science ®Google Scholar
• Eeckhout Y., Vaes G. Further studies on the activation of procollagenase, the latent precursor of bone collagenase. Effects of lysosomal cathepsin B, plasmin and kallikrein, and spontaneous activation. Biochem. J. 1977; 166: 21–31
   PubMed Web of Science ®Google Scholar
• Dinarello C. A. The IL-1 family and inflammatory diseases. Clin. Exp. Rheumatol. 2002; 20(5 Suppl 27)S1–13
   PubMed Web of Science ®Google Scholar
• Kleinert H., Schwarz P. M., Förstermann U. Regulation of the expression of inducible nitric oxide synthase. Biol. Chem. 2003; 384: 1343–1364
   PubMed Web of Science ®Google Scholar
• Li H., Wallerath T. and U. Förstermann, Physiological mechanisms regulating the expression of endothelial-type NO synthase. Nitric Oxide 2002; 7: 132–147
   PubMed Web of Science ®Google Scholar
• Gatti R. M., Radi R., Augusto O. Peroxynitrite-mediated oxidation of albumin to the protein-thiyl free radical. FEBS Lett. 1994; 348: 287–290
   PubMed Web of Science ®Google Scholar
• Kannan S. Free radical theory of autoimmunity. Theor. Biol. Med. Model 2006; 3: 22–36
   PubMedGoogle Scholar
• Kurien B. T., Hensley K., Bachmann M., Scofield R. H. Oxidatively modified autoantigens in autoimmune diseases. Free Radic. Biol. Med. 2006; 41: 549–556
   PubMed Web of Science ®Google Scholar
• Del Carlo M., Schwartz D., Erickson E. A., Loeser R. F. Endogenous production of reactive oxygen species is required for stimulation of human articular chondrocyte matrix metalloproteinase production by fibronectin fragments. Free Radic. Biol. Med. 2007; 42: 1350–1358
   PubMed Web of Science ®Google Scholar
• Lu Y., Wahl L. M. Oxidative stress augments the production of matrix metalloproteinase-1, cyclooxygenase-2, and prostaglandin E2 through enhancement of NF-kappa B activity in lipopolysaccharide-activated human primary monocytes. J. Immunol. 2005; 175: 5423–5429
   PubMed Web of Science ®Google Scholar
• Nelson K. K., Melendez J. A. Mitochondrial redox control of matrix metalloproteinases. Free Radic. Biol. Med. 2004; 37: 768–784
   PubMed Web of Science ®Google Scholar
• Billinghurst R. C., Dahlberg L., Ionescu M., Reiner A., Bourne R., Rorabeck C., Mitchell P., Hambor J., Diekmann O., Tschesche H., Chen J., Van Wart H., Poole A. R. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J. Clin. Invest. 1997; 99: 1534–1545
   PubMed Web of Science ®Google Scholar
• Brenneisen P., Briviba K., Wlaschek M., Wenk J., Scharffetter-Kochanek K. Hydrogen peroxide (H2O2) increases the steady-state mRNA levels of collagenase/MMP-1 in human dermal fibroblasts. Free Radic. Biol. Med. 1997; 22: 515–524
   PubMed Web of Science ®Google Scholar
• Saari H., Suomalainen K., Lindy O., Konttinen Y. T., Sorsa T. Activation of latent human neutrophil collagenase by reactive oxygen species and serine proteases. Biochem. Biophys. Res. Commun. 1990; 171: 979–987
   PubMed Web of Science ®Google Scholar
• Ridnour L. A., Windhausen A. N., Isenberg J. S., Yeung N., Thomas D. D., Vitek M. P., Roberts D. D., Wink D. A. Nitric oxide regulates matrix metalloproteinase-9 activity by guanylyl-cyclase-dependent and -independent pathways. Proc. Natl. Acad. Sci. U. S. A. 2007; 104: 16898–16903
   PubMed Web of Science ®Google Scholar
• van Dalen C. J., Winterbourn C. C., Kettle A. J. Mechanism of nitrite oxidation by eosinophil peroxidase: implications for oxidant production and nitration by eosinophils. Biochem. J. 2006; 394: 707–713
   PubMedGoogle Scholar
• Hawkins C. L., Brown B. E., Davies M. J. Hypochlorite- and hypobromite-mediated radical formation and its role in cell lysis. Arch. Biochem. Biophys. 2001; 395: 137–145
   PubMedGoogle Scholar
• Rees M. D., McNiven T. N., Davies M. J. Degradation of extracellular matrix and its components by hypobromous acid. Biochem. J. 2007; 401: 587–596
   PubMed Web of Science ®Google Scholar
• Rees M. D., Hawkins C. L., Davies M. J. Hypochlorite and superoxide radicals can act synergistically to induce fragmentation of hyaluronan and chondroitin sulphates. Biochem. J. 2004; 381: 175–184
   PubMed Web of Science ®Google Scholar
• Kennett E. C., Davies M. J. Degradation of matrix glycosaminoglycans by peroxynitrite/peroxynitrous acid: evidence for a hydroxyl-radical-like mechanism. Free Radic. Biol. Med. 2007; 42: 1278–1289
   PubMed Web of Science ®Google Scholar
• Sorsa T., Saari H., Konttinen Y. T., Suomalainen K., Lindy S., Uitto V. J. Non-proteolytic activation of latent human neutrophil collagenase and its role in matrix destruction in periodontal diseases. Int. J. Tissue. React. 1989; 11: 153–159
   PubMedGoogle Scholar
• Zhao W., Diz D. I., Robbins M. E. Oxidative damage pathways in relation to normal tissue injury. Br. J. Radiol. 2007; 80: S23–31, (Spec No 1)
   PubMed Web of Science ®Google Scholar
• Mastruzzo C., Crimi N., Vancheri C. Role of oxidative stress in pulmonary fibrosis. Monaldi Arch. Chest. Dis. 2002; 57: 173–176
   PubMedGoogle Scholar
• Poli G. Pathogenesis of liver fibrosis: role of oxidative stress. Mol. Aspects Med. 2000; 21: 49–98
   PubMedGoogle Scholar
• Poli G., Parola M. Oxidative damage and fibrogenesis. Free Radic. Biol. Med. 1997; 22: 287–305
   PubMed Web of Science ®Google Scholar
• Kosmehl H., Berndt A., Katenkamp D. Molecular variants of fibronectin and laminin: structure, physiological occurrence and histopathological aspects. Virchows Arch. 1996; 429: 311–322
   PubMedGoogle Scholar
• Brenmoehl J., Lang M., Hausmann M., Leeb S. N., Falk W., Scholmerich J., Goke M., Rogler G. Evidence for a differential expression of fibronectin splice forms ED-A and ED-B in Crohn's disease (CD) mucosa. Int. J. Colorectal Dis. 2007; 22: 611–623
   PubMedGoogle Scholar
• Schenk S., Quaranta V. Tales from the crypt[ic] sites of the extracellular matrix. Trends Cell. Biol. 2003; 13: 366–375
   PubMed Web of Science ®Google Scholar
• Kovacs E. J., DiPietro L. A. Fibrogenic cytokines and connective tissue production. FASEB J. 1994; 8: 854–861
   PubMed Web of Science ®Google Scholar
• Warnock M. G., Goodacre J. A. Cryptic T-cell epitopes and their role in the pathogenesis of autoimmune diseases. Br. J. Rheumatol. 1997; 36: 1144–1150
   PubMedGoogle Scholar
• Lanzavecchia A. How can cryptic epitopes trigger autoimmunity?. J. Exp. Med. 1995; 181: 1945–1948
   PubMed Web of Science ®Google Scholar
• Djaballah H. Antigen processing by proteasomes: insights into the molecular basis of crypticity. Mol. Biol. Rep. 1997; 24: 63–67
   PubMedGoogle Scholar
• Davis G. E., Bayless K. J., Davis M. J., Meininger G. A. Regulation of tissue injury responses by the exposure of matricryptic sites within extracellular matrix molecules. Am. J. Pathol. 2000; 156: 1489–1498
   PubMed Web of Science ®Google Scholar
• Van den Steen P. E., Proost P., Brand D. D., Kang A. H., Van Damme J., Opdenakker G. Generation of glycosylated remnant epitopes from human collagen type II by gelatinase B. Biochemistry 2004; 43: 10809–10816
   PubMed Web of Science ®Google Scholar
• Xu J., Rodriguez D., Petitclerc E., Kim J. J., Hangai M., Moon Y. S., Davis G. E., Brooks P. C. Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J. Cell Biol. 2001; 154: 1069–1079
   PubMed Web of Science ®Google Scholar
• Ingham K. C., Brew S. A., Erickson H. P. Localization of a cryptic binding site for tenascin on fibronectin. J. Biol. Chem. 2004; 279: 28132–28135
   PubMedGoogle Scholar
• Faisal Khan K. M., Laurie G. W., McCaffrey T. A., Falcone D. J. Exposure of cryptic domains in the alpha 1-chain of laminin-1 by elastase stimulates macrophages urokinase and matrix metalloproteinase-9 expression. J. Biol. Chem. 2002; 277: 13778–13786
   PubMed Web of Science ®Google Scholar
• Fukai F., Ohtaki M., Fujii N., Yajima H., Ishii T., Nishizawa Y., Miyazaki K., Katayama T. Release of biological activities from quiescent fibronectin by a conformational change and limited proteolysis by matrix metalloproteinases. Biochemistry 1995; 34: 11453–11459
   PubMed Web of Science ®Google Scholar
• Nissim A., Winyard P. G., Corrigall V., Fatah R., Perrett D., Panayi G., Chernajovsky Y. Generation of neoantigenic epitopes after posttranslational modification of type II collagen by factors present within the inflamed joint. Arthritis Rheum. 2005; 52: 3829–3838
   PubMed Web of Science ®Google Scholar
• Makrygiannakis D., af Klint E., Lundberg I. E., Löfberg R., Ulfgren A. K., Klareskog L., Catrina A. I. Citrullination is an inflammation-dependent process. Ann. Rheum. Dis. 2006; 65: 1219–1222
   PubMed Web of Science ®Google Scholar
• Burkhardt H., Sehnert B., Bockermann R., Engström A., Kalden J. R., Holmdahl R. Humoral immune response to citrullinated collagen type II determinants in early rheumatoid arthritis. Eur. J. Immunol. 2005; 35: 1643–1652
   PubMed Web of Science ®Google Scholar
• Bang H., Egerer K., Gauliard A., Lüthke K., Rudolph P. E., Fredenhagen G., Berg W., Feist E., Burmester G. R. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum. 2007; 56: 2503–2511
   PubMed Web of Science ®Google Scholar
• Chang X., Yamada R., Suzuki A., Kochi Y., Sawada T., Yamamoto K. Citrullination of fibronectin in rheumatoid arthritis synovial tissue. Rheumatology (Oxford) 2005; 44: 1374–1382
   PubMedGoogle Scholar
• Mott J. D., Werb Z. Regulation of matrix biology by matrix metalloproteinases. Curr. Opin. Cell Biol. 2004; 16: 558–564
   PubMed Web of Science ®Google Scholar
• Moshage H. Cytokines and the hepatic acute phase response. J. Pathol. 1997; 18: 257–266
   Google Scholar
• Leroy V., Monier F., Bottari S., Trocme C., Sturm N., Hilleret M. N., Morel F., Zarski J. P. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am. J. Gastroenterol. 2004; 99: 271–279
   PubMed Web of Science ®Google Scholar
• Giannelli G., Quaranta V., Antonaci S. Tissue remodeling in liver diseases. Histol. Histopathol. 2003; 18: 1267–1274
   PubMedGoogle Scholar
• Iredale J. P. Model of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J. Clin. Invest. 2007; 117: 539–548
   PubMed Web of Science ®Google Scholar
• Punzi L., Betterle C. Chronic autoimmune thyroiditis and rheumatic manifestations. Joint Bone Spine 2004; 71: 275–283
   PubMed Web of Science ®Google Scholar
• Dayan C. M., Daniels G. H. Chronic autoimmune thyroiditis. New Engl. J. Med. 1996; 335: 99–105
   PubMed Web of Science ®Google Scholar
• Chen K., Wei Y., Sharp G. C., Braley-Mullen H. Inhibition of TGFbeta1 by anti-TGFbeta1 antibody or lisinopril reduces thyroid fibrosis in granulomatous experimental autoimmune thyroiditis. J. Immunol. 2002; 169: 6530–6538
   PubMedGoogle Scholar
• Yazawa N., Fujimoto M., Tamaki K. Recent advances on pathogenesis and therapies in systemic sclerosis. Clin. Rev. Allergy Immunol 2007; 33: 107–112
   PubMedGoogle Scholar
• Varga J., Jimenez S. A. Modulation of collagen gene expression: its relation to fibrosis in systemic sclerosis and other disorders. Annals Int. Med. 1995; 122: 60–62
   PubMedGoogle Scholar
• Abraham D. J., Varga J. Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol. 2005; 26: 587–595
   PubMed Web of Science ®Google Scholar
• Medina C., Radomski M. W. Role of matrix metalloproteinases in intestinal inflammation. J. Pharmacol. Exp. Ther. 2006; 318: 933–938
   PubMed Web of Science ®Google Scholar
• Naito Y., Yoshikawa T. Role of matrix metalloproteinases in inflammatory bowel disease. Mol. Aspects Med. 2005; 26: 379–390
   PubMedGoogle Scholar
• von Lampe B., Barthel B., Coupland S. E., Riecken E. O., Rosewicz S. Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut 2000; 47: 63–73
   PubMed Web of Science ®Google Scholar
• Menzel K., Hausmann M., Obermeier E., Schreiter K., Dunger N., Bataille F., Falk W., Scholmerich J., Herfarth H., Rogler G., Cathepsins B. L and D in inflammatory bowel disease macrophages and potential therapeutic effects of cathepsin inhibition in vivo. Clin. Exp. Immunol. 2006; 146: 169–180
   PubMed Web of Science ®Google Scholar
• Stumpf M., Cao W., Klinge U., Klosterhalfen B., Junge K., Krones C. J., Schumpelick V. Reduced expression of collagen type I and increased expression of matrix metalloproteinases 1 in patients with Crohn's disease. J. Invest. Surg. 2005; 18: 33–38
   PubMed Web of Science ®Google Scholar
• Gööz M., Shaker M., Gööz P., Smolka A. J. Interleukin 1beta induces gastric epithelial cell matrix metalloproteinase secretion and activation during Helicobacter pylori infection. Gut 2003; 52: 1250–1256
   PubMedGoogle Scholar
• Caruso R., Fina D., Peluso I., Fantini M. C., Tosti C., Del Vecchio Blanco G., Paoluzi O. A., Caprioli F., Andrei F., Stolfi C., Romano M., Ricci V., MacDonald T. T., Pallone F., Monteleone G. IL-21 is highly produced in Helicobacter pylori-infected gastric mucosa and promotes gelatinases synthesis. J Immunol. 2007; 178: 5957–5965
   PubMedGoogle Scholar
• Lagente V., Manoury B., Nenan S., Le Quement C., Martin-Chouly C., Boichot E. Role of matrix metalloproteinases in the development of airway inflammation and remodeling. Brazilian J. Med. Biol. Res. 2005; 38: 1521–1530
   PubMed Web of Science ®Google Scholar
• Chung K. F. Inflammatory mediators in chronic obstructive pulmonary disease. Curr. Drug. Targets Inflamm. Allergy 2005; 4: 619–625
   PubMedGoogle Scholar
• Smit J. J., Lukacs N. W. The missing link: chemokine receptors and tissue matrix breakdown in COPD. Trends Pharmacol. 2006; 27: 555–557
   PubMedGoogle Scholar
• Takahashi H., Ishidoh K., Muno D., Ohwada A., Nukiwa T., Kominami E., Kira S. Cathepsin L activity is increased in alveolar macrophages and bronchoalveolar lavage fluid of smokers. Am. Rev. Respir. Dis. 1993; 147: 1562–1568
   PubMed Web of Science ®Google Scholar
• Mautino G., Oliver N., Chanez P., Bousquet J., Capony F. Increased release of matrix metalloproteinase-9 in bronchoalveolar lavage fluid and by alveolar macrophages of asthmatics. Am. J. Respir. Cell Mol. Biol. 1997; 17: 583–591
   PubMed Web of Science ®Google Scholar
• Bosse M., Chakir J., Rouabhia M., Boulet L. P., Audette M., Laviolette M. Serum matrix metalloproteinase-9: tissue inhibitor of metalloproteinase-1 ratio correlates with steroid responsiveness in moderate to severe asthma. Am. J. Respir. Crit. Care Med. 1999; 159: 596–602
   PubMed Web of Science ®Google Scholar
• Dickinson D. P. Cysteine peptidases of mammals: their biological roles and potential effects in the oral cavity and other tissues in health and disease. Crit. Rev. Oral. Biol. Med. 2002; 13: 238–275
   PubMedGoogle Scholar
• Reynolds J. J., Hembry R. M., Meikle M. C. Connective tissue degradation in health and periodontal disease and the roles of matrix metalloproteinases and their natural inhibitors. Adv. Dent. Res. 1994; 8: 312–319
   PubMedGoogle Scholar
• Salvi G. E., Lang N. P. Host response modulation in the management of periodontal diseases. J. Clin. Periodontol. 2005; 32(Suppl 6)108–129
   PubMedGoogle Scholar
• Ashley R. A. Clinical trials of a matrix metalloproteinase inhibitor in human periodontal disease. SDD Clinical Research Team. Ann. N. Y. Acad. Sci. 1999; 878: 335–346
   PubMed Web of Science ®Google Scholar
• Hernández M., Martínez B., Tejerina J. M., Valenzuela M. A., Gamonal J. MMP-13 and TIMP-1 determinations in progressive chronic periodontitis. J. Clin. Periodontol. 2007; 34: 729–735
   PubMed Web of Science ®Google Scholar
• Mohammed F. F., Smookler D. S., Khokha R. Metalloproteinases, inflammation, and rheumatoid arthritis. Ann. Rheum. Dis. 2003; 62: 43–47
   PubMedGoogle Scholar
• Holmbeck K., Szabova L. Aspect of extracellular matrix remodeling in development and disease. Birth Defects Res. (part C) 2006; 78: 11–23
   PubMedGoogle Scholar
• Charrier-Hisamuddin L., Laboisse C. L., Merlin D. ADAM- 15: a metalloprotease that mediates inflammation. FASEB J. 2008; 22: 641–653
   PubMedGoogle Scholar
• Mort J. S., Billington C. J. Articular cartilage and changes in arthritis: matrix degradation. Arthritis Res. 2001; 3: 337–341
   PubMedGoogle Scholar
• Maciewicz R. A., Wotton S. F., Etherington D. J., Duance V. C. Susceptibility of the cartilage collagens type II, IX and XI to degradation by the cysteine proteinases, cathepsins B and L. FEBS 1990; 269: 189–193
   PubMed Web of Science ®Google Scholar
• Mooney E., Gammon W. R., Jennette J. C. Characterization of the changes in matrix molecules at the dermoepidermal junction in lupus erythematosus. J. Cutan. Pathol. 1991; 18: 417–422
   PubMedGoogle Scholar
• Borza D. B., Neilson E. G., Hudson B. G. Pathogenesis of Goodpasture syndrome: a molecular perspective. Semin. Nephrol. 2003; 23: 522–531
   PubMed Web of Science ®Google Scholar
• Borza D. B. Autoepitopes and alloepitopes of type IV collagen: role in the molecular pathogenesis of anti-GBM antibody glomerulonephritis. Nephron Exp. Nephrol. 2007; 106: e37–e43
   Google Scholar
• Bolton W. K., Chen L., Hellmark T., Fox J., Wieslander J. Molecular mapping of the Goodpasture's epitope for glomerulonephritis. Trans. Am. Clin. Climatol. Assoc. 2005; 116: 229–236
   PubMedGoogle Scholar
• Woodley D. T., Chang C., Saadat P., Ram R., Liu Z., Chen M. Evidence that anti-type VII collagen antibodies are pathogenic and responsible for the clinical, histological, and immunological features of epidermolysis bullosa acquisita. J. Invest. Dermatol. 2005; 124: 958–964
   PubMed Web of Science ®Google Scholar
• KK Choi E., Gatenby P. A., McGill N. W., Bateman J. F., Cole W. G., York J. R. Autoantibodies to type II collagen: occurrence in rheumatoid arthritis, other arthritides, autoimmune connective tissue diseases and chronic inflammatory syndromes. Ann. Rheum. Dis. 1988; 47: 313–322
   PubMedGoogle Scholar
• Clague R. B., Shaw M. J., Lennox Holt P. J. Incidence of serum antibodies to native type I and type II collagens in patients with inflammatory arthritis. Annals Rheum. Dis. 1980; 39: 201–206
   PubMedGoogle Scholar
• Fujii K., Tsujii M., Kitamura A., Murota K. The diagnostic significance of anti-type II collagen antibody assay in rheumatoid arthritis. Int. Orthop. 1992; 16: 272–276
   PubMedGoogle Scholar
• Cook A. D., Mackay I. R., Cicuttini F. M., Rowley M. J. IgG subclasses of antibodies to type II collagen in rheumatoid arthritis differ from those in systemic lupus erythematosus and other connective tissue diseases. J. Rheumatol. 1997; 24: 2090–2096
   PubMedGoogle Scholar
• Yoshida M., Tsuji M., Kurosaka D., Kurosaka D., Yasuda J., Ito Y., Nishizawa T., Yamada A. Autoimmunity to citrullinated type II collagen in rheumatoid arthritis. Mod. Rheumatol. 2006; 16: 276–281
   PubMedGoogle Scholar
• Cook A. D., Gray R., Ramshaw J., Mackay I. R., Rowley M. J. Antibodies against the CB10 fragment of type II collagen in rheumatoid arthritis. Arthritis Res. Ther. 2004; 6: R477–483
   PubMed Web of Science ®Google Scholar
• Morgan K., Clague R. B., Collins I., Ayad S., Phinn S. D., Holt P. J. L. Incidence of antibodies to native and denatured cartilage collagens (type II, IX and XI) and to type I collagen in rheumatoid arthritis. Annals Rheum. Dis. 1987; 46: 902–907
   PubMed Web of Science ®Google Scholar
• Atta M. S., Lim K. L., Ala'deen D. A., Powell R. J., Todd I. Investigation of the prevalence and clinical associations of antibodies to human fibronectin in systemic lupus erythematosus. Ann. Rheum. Dis. 1995; 54: 117–124
   PubMedGoogle Scholar
• Vynios D. H., Tsagaraki I., Grigoreas G. H., Samiotaki M., Panayotou G., Kyriakopoulou D., Georgiou P., Korbakis D., Panayotou A., Nanouri K., Assouti M., Andonopoulos A. P. Autoantibodies against aggrecan in systemic rheumatic diseases. Biochimie 2006; 88: 767–773
   PubMedGoogle Scholar
• Tani Y., Sato H., Hukuda S. Autoantibodies to collagens in Japanese patients with ankylosing spondylitis. Clin. Exp. Rheumatol 1997; 15: 295–297
   PubMedGoogle Scholar
• Tiwana H., Natt R. S., Benitez-Brito R., Shah S., Wilson C., Bridger S., Harbord M., Sarner M., Ebringer A. Correlation between the immune responses to collagens type I, III, IV and V and Klebsiella pneumoniae in patients with Crohn's disease and ankylosing spondylitis. Rheumatology (Oxford) 2001; 40: 15–23
   PubMedGoogle Scholar
• Moreland L. W., Gay R. E., Gay S. Collagen autoantibodies in patients with vasculitis and systemic lupus erythematosus. Clin. Immunol. Immunopathol. 1991; 60: 412–418
   PubMedGoogle Scholar
• Petty R. E., Hunt D. W., Rosenberg A. M. Antibodies to type IV collagen in rheumatic diseases. J. Rheumatol. 1986; 13: 246–253
   PubMedGoogle Scholar
• Direskeneli H., D'Cruz D., Khamashta M. A., Hughes G. R. Autoantibodies against endothelial cells, extracellular matrix, and human collagen type IV in patients with systemic vasculitis. Clin. Immunol. Immunopathol. 1994; 70: 206–210
   PubMedGoogle Scholar
• Gabrielli A., Montroni M., Rupoli S., Caniglia M. L., DeLustro F., Danieli G. A retrospective study of antibodies against basement membrane antigens (type IV collagen and laminin) in patients with primary and secondary Raynaud's phenomenon. Arthritis Rheum. 1988; 31: 1432–1436
   PubMedGoogle Scholar
• Daskalova M., Taskov H., Dimitrova E., Baydanoff S. Humoral and cellular immune response to elastin in patients with systemic sclerosis. Autoimmunity 1997; 25: 233–241
   PubMed Web of Science ®Google Scholar
• Kobayashi S., Wada N., Kubo M. Antibodies to native type III collagen in the serum of patients with Kawasaki disease. Eur. J. Pediatr. 1992; 151: 183–187
   PubMedGoogle Scholar
• Saxena R., Sturfelt G., Nived O., Wieslander J. Significance of anti-entactin antibodies in patients with systemic lupus erythematosus and related disorders. Ann. Rheum. Dis. 1994; 53: 659–665
   PubMedGoogle Scholar
• Vecchi M. L., Radice A., Renda F., Mulé G., Sinico R. A. Anti-laminin auto antibodies in ANCA-associated vasculitis. Nephrol. Dial. Transplant. 2000; 15: 1600–1603
   PubMedGoogle Scholar
• Nishijima C., Hayakawa I., Matsushita T., Komura K., Hasegawa M., Takehara K., Sato S. Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis. Clin. Exp. Immunol. 2004; 138: 357–363
   PubMed Web of Science ®Google Scholar
• Sato S., Hayakawa I., Hasegawa M., Fujimoto M., Takehara K. Function blocking autoantibodies against matrix metalloproteinase-1 in patients with systemic sclerosis. J. Invest. Dermatol. 2003; 120: 542–547
   PubMed Web of Science ®Google Scholar
• Bei R., Mentuccia D., Trono P., Masuelli L., Cereda V., Palumbo C., Marzocchella L., Mrozek M. A., Pallotta P., Di Lella G., Modesti M., Cerilli M., Frajese G. V., Frajese G., Zambruno G., Modesti A. Immunity to extracellular matrix antigens is associated with ultrastructural alterations of the stroma and stratified epithelium basement membrane in the skin of Hashimoto's thyroiditis patients. Int. J. Immunopathol. Pharmacol. 2006; 19: 661–674
   PubMedGoogle Scholar
• De Bellis A., Sansone D., Coronella C., Conte M., Iorio S., Perrino S., Battaglia M., Bellastella G., Wall J. R., Bellastella A., Bizzarro A. Serum antibodies to collagen XIII: a further good marker of active Graves' ophthalmopathy. Clin. Endocrinol. (Oxf) 2005; 62: 24–29
   PubMed Web of Science ®Google Scholar
• Gopinath B., Musselman R., Adams C. L., Tani J., Beard N., Wall J. R. Study of serum antibodies against three eye muscle antigens and the connective tissue antigen collagen XIII in patients with Graves' disease with and without ophthalmopathy: correlation with clinical features. Thyroid 2006; 16: 967–974
   PubMed Web of Science ®Google Scholar
• Bednarczuk T., Stolarski C., Pawlik E., Slon M., Rowinski M., Kubota S., Hiromatsu Y., Bartoszewicz Z., Wall J. R., Nauman J. Autoantibodies reactive with extracellular matrix proteins in patients with thyroid-associated ophthalmopathy. Thyroid 1999; 9: 289–295
   PubMedGoogle Scholar
• Fattori B., Ghilardi P. L., Casani A., Miglirini P., Riente L. Menier's disease: role of antibodies against basement membrane antigens. Laryngoscope 1994; 104: 1290–1294
   PubMedGoogle Scholar
• Nakos G., Adams A., Andriopoulos N. Antibodies to collagen in patients with idiopathic pulmonary fibrosis. Chest 1993; 103: 1051–1058
   PubMedGoogle Scholar
• Tiwana H., Natt R. S., Benitez-Brito R., Shah S., Wilson C., Bridger S., Harbord M., Sarner M., Ebringer A. Correlation between the immune responses to collagens type I, III, IV and V and Klebsiella pneumoniae in patients with Crohn's disease and ankylosing spondylitis. Rheumatology (Oxford) 2001; 40: 15–23
   PubMedGoogle Scholar
• Chen M., O'Toole E. A., Sanghavi J., Mahmud N., Kelleher D., Weir D., Fairley J. A., Woodley D. T. The epidermolysis bullosa acquisita antigen (type VII collagen) is present in human colon and patients with crohn's disease have autoantibodies to type VII collagen. J. Invest. Dermatol. 2002; 118: 1059–1064
   PubMed Web of Science ®Google Scholar
• Oostingh G. J., Sitaru C., Zillikens D., Kromminga A., Luhrs H. Subclass distribution of type VII collagen-specific autoantibodies in patients with inflammatory bowel disease. J. Dermatol. Sci. 2005; 37: 182–184
   PubMed Web of Science ®Google Scholar
• Howard A., Dean D., Cooper S., Kirtshig G., Wojnarowska F. Circulating basement membrane zone antibodies are found in lichen sclerosus of the vulva. Australas. J. Dermatol. 2004; 45: 12–15
   PubMedGoogle Scholar
• Cooper S. M., Dean D., Allen J., Kirtschig G., Wojnarowska F. Erosive lichen planus of the vulva: weak circulating basement membrane zone antibodies are present. Clin. Exp. Dermatol. 2005; 30: 551–556
   PubMedGoogle Scholar
• Jonsson R., Pitts A., Lue C., Gay S., Mestecky J. Immunoglobulin isotype distribution of locally produced autoantibodies to collagen type I in adult periodontitis. Relationship to periodontal treatment. J. Clin. Periodontol. 1991; 18: 703–707
   PubMed Web of Science ®Google Scholar
• De-Gennaro L. A., Lopes J. D., Mariano M. Autoantibodies directed to extracellular matrix components in patients with different clinical forms of periodontitis. J. Periodontol. 2006; 77: 2025–2030
   PubMedGoogle Scholar
• Kamphuis S., Hrafnkelsdottir K., Klein M. R., de Jager W., Haverkamp M. H., van Bilsen J. H., Albani S., Kuis W., Wauben M. H., Prakken B. J. Novel self-epitopes derived from aggrecan, fibrillin, and matrix metalloproteinase-3 drive distinct autoreactive T-cell responses in juvenile idiopathic arthritis and in health. Arthritis Res. Ther. 2006; 8: R178–187
   PubMed Web of Science ®Google Scholar
• Snowden N., Reynolds I., Morgan K., Holt L. T cell responses to human type II collagen in patients with rheumatoid arthritis and healthy controls. Arthritis Rheum. 1997; 40: 1210–1218
   PubMedGoogle Scholar
• Kim W. U., Kim K. J. T cell proliferative response to type II collagen in the inflammatory process and joint damage in patients with rheumatoid arthritis. J. Rheumatol. 2005; 32: 225–230
   PubMedGoogle Scholar
• Park S. H., Min D. J., Cho M. L., Kim W. U., Youn J., Park W., Cho C. S., Kim H. Y. Shift toward T helper 1 cytokines by type II collagen-reactive T cells in patients with rheumatoid arthritis. Arthritis Rheum. 2001; 44: 561–569
   PubMedGoogle Scholar
• Ohnishi Y., Tsutsumi A., Sakamaki T., Sumida T. T cell epitopes of type II collagen in HLA-DRB1*0101 or DRB1*0405-positive Japanese patients with rheumatoid arthritis. Int. J. Mol. Med. 2003; 11: 331–335
   PubMed Web of Science ®Google Scholar
• Kim H. Y., Kim W. U., Cho M. L., Lee S. K., Youn J., Kim S. I., Yoo W. H., Park J. H., Min J. K., Lee S. H., Park S. H., Cho C. S. Enhanced T cell proliferative response to type II collagen and synthetic peptide CII (255–274) in patients with rheumatoid arthritis. Arthritis Rheum. 1999; 42: 2085–2093
   PubMed Web of Science ®Google Scholar
• ter Steege J., Vianen M., van Bilsen J., Bijlsma J., Lafeber F., Wauben M. Identification of self-epitopes recognized by T cells in rheumatoid arthritis demonstrates matrix metalloproteinases as a novel T cell target. J. Rheumatol. 2003; 30: 1147–1156
   PubMedGoogle Scholar
• Zou J., Appel H., Rudwaleit M., Thiel A., Sieper J. Analysis of the CD8+ T cell response to the G1 domain of aggrecan in ankylosing spondylitis. Ann. Rheum. Dis. 2005; 64: 722–729
   PubMed Web of Science ®Google Scholar
• Zou J., Zhang Y., Thiel A., Rudwaleit M., Shi S. L., Radbruch A., Poole R., Braun J., Sieper J. Predominant cellular immune response to the cartilage autoantigenic G1 aggrecan in ankylosing spondylitis and rheumatoid arthritis. Rheumatology (Oxford) 2003; 42: 846–855
   PubMed Web of Science ®Google Scholar
• Guerassimov A., Zhang Y., Cartman A., Rosenberg L. C., Esdaile J., Fitzcharles M. A., Robin Poole A. Immune responses to cartilage link protein and the G1 domain of proteoglycan aggregan in patients with osteoarthritis. Arthriis Rheum. 1999; 42: 527–533
   PubMedGoogle Scholar
• Zillikens D., Giudice G. J. BP180/type XVII collagen: its role in acquired and inherited disorders or the dermal-epidermal junction. Arch. Dermatol. Res. 1999; 291: 187–194
   PubMedGoogle Scholar
• Courtenay J. S., Dallman M. J., Dayan A. D., Martin A., Mosedale B. Immunisation against heterologous type II collagen induces arthritis in mice. Nature 1980; 283: 666–668
   PubMed Web of Science ®Google Scholar
• Hansson A. S., Lu S., Holmdahl R. Extra-articular cartilage affected in collagen-induced, but not pristane-induced, arthritis models. Clin. Exp. Immunol. 2002; 127: 37–42
   PubMedGoogle Scholar
• Holmdahl R., Jansson L., Larsson A., Jonsson R. Arthritis in DBA/1 mice induced with passively transferred type II collagen immune serum. Immunohistopathology and serum levels of anti-type II collagen auto-antibodies. Scand. J. Immunol. 1990; 31: 147–157
   PubMedGoogle Scholar
• Kuhn K. A., Kulik L., Tomooka B., Braschler K. J., Arend W. P., Robinson W. H., Holers V. M. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J. Clin. Invest. 200; 116: 961–973
   Google Scholar
• Adarichev V. A., Glant T. T. Experimental spondyloarthropathies: animal models of ankylosing spondylitis. Curr. Rheumatol. Rep. 2006; 8: 267–274
   PubMedGoogle Scholar
• Murad Y. M., Szabó Z., Ludányi K., Glant T. T. Molecular manipulation with the arthritogenic epitopes of the G1 domain of human cartilage proteoglycan aggrecan. Clin. Exp. Immunol. 2005; 142: 303–311
   PubMedGoogle Scholar
• Glant T. T., Mikecz K. Proteoglycan aggrecan-induced arthritis: a murine autoimmune model of rheumatoid arthritis. Methods Mol. Med. 2004; 102: 313–338
   PubMedGoogle Scholar
• Teodoro W. R., Velosa A. P., Witzel S. S., Garippo A. L., Farhat C., Parra E. R., Sonohara S., Capelozzi V. L., Yoshinari N. H. Architectural remodeling in lungs of rabbits induced by type V collagen immunization: a preliminary morphologic model to study diffuse connective tissue diseases. Pathol. Res. Pract. 2004; 200: 681–691
   PubMed Web of Science ®Google Scholar
• Murphy-Ullrich J. E., Oberley T. D. and D.F Mosher, Detection of autoantibodies and glomerular injury in rabbits immunized with denatured human fibronectin monomer. Am. J. Pathol. 1984; 117: 1–11
   PubMedGoogle Scholar
• van Bruggen M. C., Kramers C., Hylkema M. N., Smeenk R. J., Berden J. H. Significance of anti-nuclear and anti-extracellular matrix autoantibodies for albuminuria in murine lupus nephritis; a longitudinal study on plasma and glomerular eluates in MRL/l mice. Clin. Exp. Immunol. 1996; 105: 132–139
   PubMed Web of Science ®Google Scholar
• Zhou X., Tan F. K., Milewicz D. M., Guo X., Bona C. A., Arnett F. C. Autoantibodies to fibrillin-1 activate normal human fibroblasts in culture through the TGF-beta pathway to recapitulate the “scleroderma phenotype.”. J. Immunol. 2005; 175: 4555–4560
   PubMedGoogle Scholar
• Ai J., Leonhardt J. M., Heymann W. R. Autoimmune thyroid diseases: etiology, pathogenesis, and dermatologic manifestations. J. Am. Acad. Dermatol. 2003; 48: 641–659
   PubMed Web of Science ®Google Scholar
• Kim W. U., Cho M. L., Jung Y. O., Min S. Y., Park S. W., Min D. J., Yoon J. H., Kim H. Y. Type II collagen autoimmunity in rheumatoid arthritis. Am. J. Med. Sci. 2004; 327: 202–211
   PubMed Web of Science ®Google Scholar